DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 ...

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

In addition to Jefferies, Dexcom also received a Buy from Canaccord Genuity’s William Plovanic in a report issued today. However, on the same day, Barclays maintained a Sell rating on Dexcom (NASDAQ: ...

DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...

In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago. These figures are ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...